Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series. (PubMed, Gastro Hep Adv) - Sep 19, 2026 - "Median prednisone-equivalent dose decreased from 30 mg/day at baseline to 12.5 mg/day at 48 weeks (-58.3%). In this prospective cohort of difficult-to-manage AIH, rituximab produced early biochemical improvement and a sustained corticosteroid-sparing effect, but a durable biochemical remission was uncommon. These data support further prospective evaluation of rituximab and next-generation B-cell-directed therapies in refractory AIH."
Journal • Autoimmune Hepatitis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure
|
|
Craig Lammert; Divya Minnaganti; Kelsey Green; Maaz Arif; Nadia Blessing; Naga Chalasani; Raj Vuppalanchi; Regina Weber
|